Quantcast

Latest Lilly Stories

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-06-02 08:26:14

INDIANAPOLIS, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and...

2014-05-30 04:22:13

HILDEN, Germany, and GERMANTOWN, Maryland, May 30, 2014 /PRNewswire/ -- - Fourth oncology project with Lilly expands QIAGEN's Personalized Healthcare pipeline - Development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with innovative cancer therapies under development by Lilly - Project to include assays for QIAGEN's new multi-modal, multi-analyte Modaplex...

2014-05-28 08:30:29

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the...

2014-05-27 16:25:01

INDIANAPOLIS, May 27, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 16 for the media and investment community to provide detailed updates for dulaglutide, its investigational glucagon-like receptor agonist (GLP-1) being studied for the treatment of type 2 diabetes. The call, which is being held in conjunction with the 74(th )American Diabetes Association Scientific Sessions, will include updates on Phase III data for dulaglutide,...

2014-05-22 16:26:51

INDIANAPOLIS, May 22, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 30(th) Annual Sanford C. Bernstein Strategic Decisions Conference on Wednesday, May 28, 2014. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer, will participate in a fireside chat at 3:00 p.m. EDT. A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm....

2014-05-16 23:06:45

Study looks at Panama and Miami as ideal distribution hub to Latin America. Miami, FL (PRWEB) May 16, 2014 Florida International University (FIU) Masters of International Business (MIB) students and international freight forwarder LILLY + Associates International released a semester-long study weighing the benefits between PortMiami and Panama as the natural distribution hub for the Americas. "The meticulous level of work performed by the FIU MIB students, under the direction of...

2014-05-16 08:27:01

INDIANAPOLIS, May 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 3, 2014 for the media and investment community to review select data presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The conference call will be held from 3:00 - 4:30 p.m. U.S. Eastern Daylight Time (EDT). Investors, media and the general public can access the live conference call through a link that will be posted on Lilly's...

2014-05-15 23:15:20

Medical ID featuring NASCAR driver Ryan Reed will raise funds and awareness for the American Diabetes Association. Houston, TX (PRWEB) May 15, 2014 Ryan Reed, the driver of the No. 16 Drive to Stop Diabetes℠ presented by Lilly Diabetes Roush Fenway Racing Ford Mustang, is racing through the NASCAR Nationwide Series season while becoming a role model for those facing diabetes. His signature and recognizable No. 16 are prominently featured on a limited edition medical ID bracelet being...

2014-05-15 04:22:50

INDIANAPOLIS, May 15, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the English High Court has determined that the vitamin dosage regimen patents for Alimta(®) (pemetrexed) would not be infringed by a generic competitor that has stated an intent to market certain alternative salt forms of pemetrexed in several European countries upon expiry of the Alimta compound patents in 2015. The decision came in the case of Actavis UK Limited and others v. Eli Lilly...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.